Viewing Study NCT01142466

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 4:21 PM

Ignite Modification Date: 2025-12-26 @ 1:54 PM

Study NCT ID: NCT01142466

Status: COMPLETED

Last Update Posted: 2014-02-27

First Post: 2010-06-10

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone

Sponsor: Merck KGaA, Darmstadt, Germany

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module Adverse Events Module Baseline Characteristics Module Participant Flow Module